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chestjournal.orgBACKGROUND: Phenotypic characteristics of patients with eosinophilic and noneosinophilic
asthma are not well characterized in global, real-life severe asthma cohorts.
RESEARCHQUESTION: What is the prevalence of eosinophilic and noneosinophilic phenotypes
in the population with severe asthma, and can these phenotypes be differentiated by clinical
and biomarker variables?
STUDY DESIGN ANDMETHODS: This was an historical registry study. Adult patients with severe
asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the In-
ternational Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized
according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic
algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional
exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical char-
acteristics were defined at baseline (ie, 1 year before or closest to date of BEC).
RESULTS: One thousand seven hundred sixteen patients with prospective data were included;
83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and
6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of pa-
tients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie,
grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung
function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P ¼ .027) than those with a
noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be
women (81.5% vs 62.9%; P ¼ .047), to have eczema (20.8% vs 8.5%; P ¼ .003), and to use
anti-IgE (32.1% vs 13.4%; P ¼ .004) and leukotriene receptor antagonists (50.0% vs 28.0%;
P ¼ .011) add-on therapy.
INTERPRETATION: According to this multicomponent, consensus-driven, and evidence-based
eosinophil gradient algorithm (using variables readily accessible in real life), the severe
asthma eosinophilic phenotype was more prevalent than previously identified and was
phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in
primary and specialist care, addressing inherent issues of phenotype heterogeneity and
phenotype instability. Identification of treatable traits across phenotypes should improve
therapeutic precision. CHEST 2021; 160(3):814-830KEYWORDS: Asia; Europe; International Severe Asthma Registry; Middle East; North AmericaFOR EDITORIAL COMMENT, SEE PAGE 789tal, Sydney, Australia; Respiratory &
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hest.2021.04.013The knowledge that asthma represents a spectrum of
diverse types is nothing new. In line with the Lancet
Asthma Commission recommendations, asthma should
be deconstructed into its various and heterogeneous
types to answer the questions: What sort of asthma does
the patient have?, What are the components of the
airway disease?, and What are the treatable traits?1,2 In
particular, the term severe asthma includes many
different phenotypes and endotypes that differ in their
clinical presentation, underlying pathways, and response
to treatment.3
Eosinophilic airways inflammation has emerged as the
hallmark of one type of severe asthma, so much so that
asthma is classified routinely as eosinophilic or
noneosinophilic.4 Brown5 was the first to identify the
corticosteroid-responsive eosinophilic asthma
phenotype in 1958. This eosinophilic inflammation is815
Take-home Points
Study Question: What is the prevalence of eosino-
philic and noneosinophilic phenotypes in the popu-
lation with severe asthma, and can these phenotypes
be differentiated by clinical and biomarker variables?
Results: Of 1,716 patients included, 83.8%, most
likely had an eosinophilic phenotype. These patients
were older, had later disease onset asthma, and
showed worse lung function compared with those
with a noneosinophilic phenotype (1.6%).
Interpretation: The severe asthma eosinophilic
phenotype is more prevalent than previously thought
and is phenotypically distinct when defined using
variables readily accessible in real life.driven predominantly by type 2 inflammation, including
T-helper cells type 2 and group 2 innate lymphoid cells.
It is mediated by IL-4, IL-5, IL-13, and granulocyte
macrophage-colony stimulating factor and can be
predicted (to some extent) from elevated fractional
exhaled nitric oxide (FENO) concentration and sputum or
blood eosinophilia.6 Noneosinophilic asthma
traditionally has been defined more arbitrarily as asthma
without features of T-helper cell type 2 asthma and
generally is based on the presence of neutrophils in
sputum or the absence (or normal levels) of eosinophils
or other T2 markers in sputum, biopsy samples, or
blood.7
Knowledge of the presenting phenotype can help to
predict asthma attack risk and health care resource
use,8,9 to inform targeted treatment, and to predict
treatment response.10,11 This eosinophil-targeted
approach also has the advantage of reducing oral
corticosteroid (OCS) use, which decreases risk of serious
adverse events12 and attenuates rates of severe
exacerbations.13 Noneosinophilic severe asthma needs to
be characterized better if similar advancements in its
treatment are to be made.
According to the Global Initiative for Asthma (GINA),
the eosinophilic phenotype is found in approximately
50% of people with severe asthma.14 Cluster analyses
from different asthma cohorts have identified several
asthma phenotypes (mostly eosinophilic) using a range
of demographic and clinical characteristics to describe
them.15 However, substantial overlap was noted among816 Original Researchphenotypes, most likely because of differences in sample
population, geographic variation, variables assessed, and
statistical methods used. Additionally, presence of
comorbidities, exposures, OCS use, and FENO were not
included in all cluster descriptions. Therefore, a need
exists to characterize asthma phenotypes better in a
large, multinational, real-life cohort of patients with
severe asthma, considering the effect of steroids on type
2 biomarker concentrations and the importance of
multiple blood eosinophil count (BEC) measurements
when defining phenotypes. A more detailed
deconstruction of asthma into its component types has
the potential to make personalized treatment a reality
for patients with asthma, effectively jump-starting the
so-called stalled asthma outcomes and asthma mortality
trends that have remained unchanged for years.2
A combination of clinical characteristics and biomarkers
may be a better way to characterize asthma types. GINA
recommends using different combinations of factors to
identify type 2 inflammatory phenotypes, including
BEC, FENO, sputum eosinophils, need for maintenance
OCS (mOCS) and presence of multiple comorbidities.16
Only one study previously proposed a diagnostic scheme
to determine severe eosinophilic asthma, which was
agreed by severe asthma expert consensus.17 However, it
has not yet been applied to a real-life clinical setting. The
International Severe Asthma Registry (ISAR; http://
isaregistries.org/), the largest adult severe asthma
registry in the world, has sufficient power to investigate,
characterize, quantify, and compare eosinophilic and
noneosinophilic phenotypes and covers diverse
jurisdictions, facilitating the generalizability of findings
to the wider severe asthma population. ISAR captures
BEC and many other variables associated with severe
eosinophilic asthma (eg, FENO, age at onset,
comorbidities, atopic status, and mOCS use),18,19
enabling the development of a multicomponent, expert-
endorsed algorithm for use in real life.
The aim of our study was (1) to describe an algorithm to
characterize better severe eosinophilic and
noneosinophilic asthma using both phenotype
characteristics and biomarkers, (2) to quantify the
proportion of patients with severe asthma with these
phenotypes in the largest real-life severe asthma cohort
in the world (ie, ISAR), and (3) to describe and compare
their demographic and clinical characteristics.[ 1 6 0 # 3 CHES T S E P T EM B E R 2 0 2 1 ]
Methods
Study Design and Data Source
This was a historical registry study to quantify and characterize
eosinophilic and noneosinophilic severe asthma for patients enrolled
in ISAR from January 1, 2015, through September 30, 2019.19
Prospective, de-identified patient data incorporating standardized
variables from new and pre-existing severe asthma registries were
pooled from 11 countries (Bulgaria, Canada, Denmark, Greece, Italy,
Japan, Kuwait, South Korea, Spain, the United Kingdom, and the
United States). A full description of variables collected is provided in
e-Table 1, including demographic variables (eg, age, age at onset, sex,
race) as well as details on asthma attack rate, asthma control status,
presence of atopy and comorbidities, biomarker concentrations (eg,
IgE and FENO), lung function, and treatment regimen. A full
description of how ISAR works has been published previously.20
Details on compliance with local and international codes and
regulations are provided in e-Appendix 1.Patients
Patients were required to be aged 18 years of age or older at
enrolment, to have severe asthma (ie, receiving treatment at
GINA 2018 step 5 or with uncontrolled asthma at GINA step 4)21
with $ 1 BEC recorded. A summary of how each registry
diagnoses asthma and categorizes severe asthma is provided in e-




















Figure 1 – Flow chart showing original eosinophilic and noneosinophilic seve
fractional exhaled nitric oxide; OCS ¼ oral corticosteroid.
chestjournal.orgDevelopment of Gradient Eosinophilic Phenotype
Algorithm
A gradient eosinophilic phenotype algorithm was developed after an
extensive literature review as well as discussions with and consensus
of experts in the ISAR Steering Committee (comprising scientists,
clinicians, and epidemiologists) (e-Fig 1). Consensus was achieved
after several face-to-face meetings and via e-mail correspondence
(e-Appendix 1). This group of experts selected variables used to
inform the algorithm and agreed on cutoff values, based on
published evidence and feasibility of availability in real-life clinical
practice, but without knowledge of how selection of these
variables (or their cutoffs) would influence eosinophil phenotype
grading in the present cohort. These variables and cutoffs
included highest BEC ever ($ 300 cells/mL, $ 150-300 cells/mL,
or <150 cells/mL), anti-IL-5/5 receptor treatment, long-term OCS
use ever, elevated FENO ($ 25 parts per billion) ever, nasal polyps
diagnosis ever, and adult asthma onset ($ 18 years) and were
informed by the published evidence base and asthma management
guidelines.16,22-27 Phenotypes were classified as grade 3 (most
likely eosinophilic), grade 2 (likely eosinophilic), grade 1 (least
likely eosinophilic), and grade 0 (noneosinophilic) (Fig 1).
Patients most likely to have an eosinophilic phenotype (grade 3)
were those with highest BEC ever of $ 300 cells/mL or receiving
anti-IL-5/anti-IL-5 receptor therapy, or with BEC of $ 150 to 300
cells/mL with (1) mOCS or (2) $ 2 of nasal polyps, elevated FENO,
or late onset of disease. The noneosinophilic phenotype (grade 0)
was defined by experts as highest BEC ever of < 150 cells/mL in & < 300
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Grade 3: Most likely
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the absence of nasal polyps, elevated FENO, late onset, or mOCS. See
Figure 1 for definitions of grade 1 and 2 eosinophilic phenotypes.
Description of Eosinophilic and Noneosinophilic Severe
Asthma Phenotypes
Both demographic and clinical variables were used to describe
eosinophilic and noneosinophilic severe asthma populations. All
demographic and clinical characteristic were obtained within 1 year
before or closest to the highest BEC recording (before anti-IL-5
therapy).
Statistical Analysis
The statistical analysis plan was predefined to reduce bias. Stata
version 14.1 software (StataCorp) was used to conduct all statistical
analyses. Descriptive statistics were computed for all demographic
and clinical characteristics by phenotype (grades 0-3) as continuous
variables or categorical measures as appropriate. For testing
differences between groups, phenotypes were collapsed into an
overall eosinophilic group (ie, grades 2 and 3) and a definitely
noneosinophilic group (ie, grade 0). Grade 1 was excluded from the818 Original Researchnoneosinophilic group because patients in this group had at least
one eosinophilic characteristic. Between-group differences in
categorical variables were tested using the c 2 test or Fisher exact
test (if n < 5). The unpaired Student t test and Wilcoxon Mann-
Whitney test were used to compare normally and nonnormally
distributed data across groups, respectively. A two-sample test was
used to compare proportions across groups. Statistical significance
was defined as P < .05.
Sensitivity Post Hoc Analyses
The original gradient eosinophilic phenotype algorithm was
reformulated without adult-onset asthma and without FENO as
criteria. The number of patients (prospective ISAR data) in each
eosinophilic and noneosinophilic phenotype was recalculated, and
demographic and clinical characteristics for each group were
reassessed. The number (percentage) of patients in each phenotype
and a summary of their demographic and clinical characteristics also
were assessed for retrospective electronic medical record (EMR) data
captured for patients with severe asthma actively managed in routine
care in the United States (ie, have at least two visits).Results
Patients
The ISAR prospective population comprised 1,716
patients (United States, n ¼ 70; United Kingdom, n ¼
712; Spain, n ¼ 217; Italy, n ¼ 163; Kuwait, n ¼ 158;
Denmark, n ¼ 127; Bulgaria, n ¼ 87; Canada, n ¼ 85;
Greece, n ¼ 35; Japan, n ¼ 34; and South Korea, n ¼
28). The ISAR retrospective population (using EMR
data) included a further 1,891 patients with severe
asthma actively managed with routine care in the United
States.
Gradient Eosinophilic Phenotype Algorithm
For the ISAR prospective population (n ¼ 1,716),
83.8% of patients were identified as most likely (grade 3)
to have an eosinophilic phenotype, 8.3% were identified
as likely (grade 2) to have an eosinophilic phenotype,
and 6.3% were identified as least likely (grade 1) to have
an eosinophilic phenotype, with 1.6% of patients being
identified as having noneosinophilic asthma (grade 0)
(Table 1). These phenotype classifications were
rechecked for robustness by cross-examining their
defining characteristics, showing an increase of age at
onset, incidence of nasal polyps, and high FENO from
grade 0 (noneosinophilic) to grade 3 (eosinophilic)
phenotypes (e-Table 4). Grade 3 (most likely)
eosinophilic phenotype predominated for patients with
severe asthma in all countries, ranging from 64% of
patients in South Korea to 93% of patients in Denmark
(Fig 2). The eosinophilic phenotype distribution was
similar when age at asthma onset and FENO were
excluded from the gradient algorithm (Table 1, e-Figs 2,
3). For the ISAR retrospective population activelyassessed in the United States (n ¼ 1,891), 74.3%, 4.1%,
and 11.5% most likely, likely, and least likely had an
eosinophilic severe asthma phenotype, respectively;
10.1% of patients had a noneosinophilic phenotype.
Demographic and Clinical Characteristics
Original Algorithm (ISAR Prospective Population,
n [ 1,716): Patients in the severe asthma cohort,
regardless of phenotype (ie, eosinophilic or
noneosinophilic severe asthma) tended to be White
(68.7% vs 74.1%), to be overweight or obese
(70.5% vs 74.0%), to be atopic (ie, specific IgE testing or
skin prick test; 88.3% vs 90.9%), to have elevated (> 150
International Units/mL) IgE concentrations
(61.8% vs 70.0%), and to have high allergic rhinitis
prevalence (65.5% vs 60.0%), with most exhibiting poor
asthma control (59.9% vs 59.3%) and multiple
exacerbations ($ 2 in the previous year; 62.0% vs 59.1%)
(Table 2). The prevalence of former smokers
(28.4% vs 34.6%), ED visits ($ 1 in the previous year;
33.9% vs 32.0%), and hospitalizations ($ 1 in the
previous year; 28.6% vs 24.0%) was high in both groups
(Table 2). Although an adherence variable was not
included in the current dataset, all patients were
receiving background asthma therapy with evidence of
persistence and good adherence (in the opinion of the
clinician or based on other evidence, such as
prescription refills).
Some differences were noted. Patients with an
eosinophilic phenotype (ie, grades 2 or 3) tended
to be older (52.4 years vs 38.8 years; P < .001), to
have later asthma onset (29.1 years vs 6.7 years;
P < .001), and to worse lung function (ie, FEV1 to FVC[ 1 6 0 # 3 CHES T S E P T EM B E R 2 0 2 1 ]
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BEC ¼ blood eosinophil count; FENO ¼ fractional exhaled nitric oxide; ISAR ¼ International Severe Asthma Registry; NP ¼ nasal polyps; OCS ¼ oral corticosteroids; ppb ¼ parts per billion.
aIndependent criteria specified in each row; before anti-IL-5/5 receptor or long-term OCS treatment was used wherever possible.
bOf 178 patients receiving anti-IL-5, 125 patients showed BEC of < 150 cells/mL (88 patients receiving maintenance OCS; 37 patients never received maintenance OCS) and 53 patients showed BEC of $ 150 - < 300
cells/mL (38 receiving maintenance OCS; 15 patients never received maintenance OCS). Of the 37 with BEC of < 150 cells/mL without OCS, 26 patients did not have a BEC available from before anti-IL-5 treatment.
Eleven patients (from Canada [n ¼ 1] Denmark [n ¼ 2], Spain [n ¼ 3] and the United States [n ¼ 5]) had a BEC available from before anti-IL-5 treatment.
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Figure 2 – Bar graph showing eosinophilic severe asthma phenotype distribution by country for prospective International Severe Asthma Registry
population (defined according to the original algorithm).ratio of < 0.7: 46.6% vs 16.7% [P ¼ .039] and
postbronchodilator % predicted FEV1: 76.1% vs 89.3%
[P ¼ .027]) than those with a noneosinophilic phenotype
(Table 2, Fig 3). Those with noneosinophilic severe asthma
(ie, grade 0) were more likely to be women
(81.5% vs 62.9%; P ¼ .047), to have eczema
(20.8% vs 8.5%; P ¼ .033), and to use anti-IgE
(32.1% vs 13.4%; P ¼ .004) and leukotriene receptor
antagonist (LTRA; 50.0% vs 28%; P ¼ .011) as an add-on
to inhaled corticosteroids plus long-acting b-agonist
therapy than those patients with an eosinophilic phenotype
(ie, grades 2 or 3) (Table 2, Fig 3). Demographic and
clinical characteristics along the eosinophil phenotype
gradient (ie, grades 0, 1, 2, and 3) are provided in e-Table 5.
Original AlgorithmWithout Age at Onset and FENO as
Phenotype-Defining Criteria (ISAR Prospective
Population, n [ 1,716) and for Those Actively
Managed in the United States (n[ 1,891; EMR Data):
A similar distribution of demographic and clinical
characteristics was observed when age at onset and FENO
were removed as defining criteria from the eosinophil
gradient algorithm (e-Tables 6 and 7). When age at
onset was excluded from the algorithm, those with
noneosinophilic severe asthma still tended to be younger
(49.6 years vs 52.3 years; P ¼ .145), to have earlier
asthma onset (27.4 years vs 28.9 years; P ¼ .637), and to
have eczema (12.5% vs 8.4%; P ¼ .291), although the820 Original Researchdifference between noneosinophilic and eosinophilic
phenotypes was less marked (e-Table 6). When FENO
was removed from the gradient algorithm, those with
noneosinophilic severe asthma still tended to be women
(75.0 years vs 62.7 years; P ¼ .096), to have eczema
(13.9% vs 8.3%; P ¼ .229), and to use add-on LTRA with
inhaled corticosteroids plus long-acting b-agonist
therapy (40.0% vs 28.0%; P ¼ .078), but the difference
was no longer significant compared with those with
eosinophilic severe asthma (e-Table 7). The
demographic and clinical characteristics for those
patients with severe asthma assessed actively in the
United States were slightly different from the ISAR
prospective data (e-Table 8).Discussion
We demonstrated that the eosinophilic severe asthma
phenotype is larger than previously estimated (ie, >
80% vs approximately 50%)14 and identified distinct
eosinophilic and noneosinophilic severe asthma patterns
based on a combination of clinical and biomarker
variables. Our proposed multicomponent eosinophil
phenotype classification algorithm is based on extensive
literature review and expert consensus, uses variables
readily accessible both in primary and specialist care,
and is linked to morbidity and treatment response.
Furthermore, the algorithm takes variability in BEC[ 1 6 0 # 3 CHES T S E P T EM B E R 2 0 2 1 ]
TABLE 2 ] Demographic and Clinical Characteristics According to Eosinophilic (Grades 2 and 3) and
Noneosinophilic (Grade 0) Phenotype, Categorized According to the Original Algorithm (ISAR
Prospective Population; N ¼ 1,716)
Characteristic Noneosinophilic (Grade 0; n ¼ 28) Eosinophilic (Grades 2 or 3; n ¼ 1,580) P Value
Sex
Nonmissing 27 (96.4) 1,571 (99.4) .047a,b
Female 22 (81.5) 988 (62.9)
Age, y
Nonmissing 26 (92.9) 1,513 (95.8)
Mean  SD 38.8  12.1 52.4  13.8 .000c,b
18-34 10 (38.5) 177 (11.7)
.000
d,b35-54 14 (53.8) 631 (41.7)
55-79 2 (7.7) 683 (45.1)
$ 80 0 (0) 22 (1.4)
Ethnicity
Nonmissing 27 (96.4) 1,549 (98.0)
.650d
White 20 (74.1) 1,064 (68.7)
Asian 3 (11.1) 140 (9.1)
Black 0 (0) 55 (3.5)
Mixed 0 (0) 12 (0.8)
Other 4 (14.8) 272 (17.6)
Unknown 0 (0) 6 (0.4)
BMI, kg/m2b
Nonmissing 27 (96.4) 1,546 (98.0)
.943d
Underweight (< 18.5) 0 (0) 25 (1.6)
Normal ($ 18.5-< 25) 7 (25.9) 431 (27.9)
Overweight ($ 25-< 30) 10 (37.0) 504 (32.6)
Obese ($ 30) 10 (37.0) 586 (37.9)
Smoking status
Nonmissing 26 (92.9) 1,540 (97.5)
.570d
Current smokers 1 (3.8) 53 (3.4)
Former smoker 9 (34.6) 438 (28.4)
Never smoker 16 (61.5) 1,049 (68.1)
Age at asthma onset, y
Nonmissing 23 (82.1) 1,493 (90.9)
Mean  SD 6.7  4.1 29.1  18.0 .000c,b
< 18 23 (100.0) 424 (29.5)
—18-29 0 (0.0) 283 (19.7)
$ 30 0 (0.0) 729 (50.8)
Comorbidities ever
Nonmissing 24 (85.7) 1,493 (94.5)
—NP 0 (0.0) 492 (32.9)
Nonmissing 14 (50.0) 851 (53.9)
CRS 6 (42.9) 448 (52.6) .467a
Nonmissing 13 (46.4) 514 (32.5)
.577a
CRS without NP 6 (46.1) 198 (38.5)
(Continued)
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TABLE 2 ] (Continued)
Characteristic Noneosinophilic (Grade 0; n ¼ 28) Eosinophilic (Grades 2 or 3; n ¼ 1,580) P Value
Nonmissing — 314 (19.9)
—
CRS with NP 0 (0.0) 234 (74.5)
Nonmissing 15 (53.6) 869 (55.0)
.658a
AR 9 (60.0) 569 (65.5)
Nonmissing 24 (85.7) 1,275 (80.7) .033a,b
Eczema 5 (20.8) 109 (8.5) —
Atopy
Nonmissing 22 (78.6) 1,362 (86.2)
.701f
Atopy 20 (90.9) 1,202 (88.3)
Asthma control
Asthma control, nonmissing 27 (96.4) 1,296 (82.0)
Poorly controlled 16 (59.3) 776 (59.9)
.828a
Not well controlled 5 (18.5) 190 (14.7)
Well controlled 6 (22.2) 330 (25.5)
Asthma attacks, nonmissing 22 (78.6) 1,354 (85.7)
Mean  SD 3.2  3.0 3.4  3.7 .919c
0 5 (22.7) 350 (25.9)
.698d
1 4 (18.2) 166 (12.3)
2 1 (4.5) 180 (13.3)
3 2 (9.1) 129 (9.6)
$ 4 10 (45.5) 529 (39.1)
Health care resource use
Invasive ventilation, nonmissing 22 (78.6) 1,395 (88.3)
Mean  SD 0.1  0.5 0.1  0.6 .724c
0 20 (90.9) 1,294 (92$8)
.442d1 1 (4.5) 75 (5.4)
$ 2 1 (4.5) 26 (1.9)
ED visit, nonmissing 25 (89.3) 1,461 (92.5)
Mean  SD 1.6  4.2 1.2  3.2 .978c
0 17 (68.0) 965 (66.0)
.912d1 2 (8.0) 161 (11.0)
$ 2 6 (24.0) 335 (22.9)
Hospitalization, nonmissing 25 (89.3) 1,446 (91.5)
Mean  SD 0.6  1.9 0.7  1.5 .676c
0 19 (76.0) 1,033 (71.4)
.808d1 2 (8.0) 202 (14.0)




20 (71.4) 1,270 (80.4)
< 150 6 (30.0) 485 (38.2)
.709a150-400 7 (35.0) 357 (28.1)
> 400 7 (35.0) 428 (33.7)
(Continued)
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TABLE 2 ] (Continued)
Characteristic Noneosinophilic (Grade 0; n ¼ 28) Eosinophilic (Grades 2 or 3; n ¼ 1,580) P Value
FENO, nonmissing, ppb 23 (82.1) 1,080 (68.4)
< 25 23 (100.0) 299 (27.7)
—$ 25-< 50 0 (0.0) 338 (31.3)
$ 50 0 (0.0) 443 (41.0)
Lung function
Post-BD FEV1 nonmissing,% predicted 14 (50.0) 823 (52.1) .027
b,e
Mean  SD 89.3  18.2 76.1  22.1
Pre-BD FEV1, % predicted n ¼ 21 n ¼ 1,174
.427e
Mean  SD 77.1  23.2 72.9  24.1
Post-BD FEV1 to FVC ratio, nonmissing 12 (42.9) 641 (40.6) .429
e
Mean  SD 0.7  0.1 0.7  0.2
< 0.7 2 (16.7) 299 (46.6) .039b,f
Reversibility, nonmissing 11 (39.3) 616 (39.0) .933c
Mean  SD 7.5  8.0 7.9  8.6
< 9% 7 (63.6) 616 (64.1) .973f
Therapy ever
Nonmissing 28 (100.0) 1,580 (100.0)
Anti-IL-5/5 receptor 0 (0.0) 790 (50.0)
—
Mepolizumab 0 (0.0) 638 (80.7)
Benralizumab 0 (0.0) 129 (16.3)
Reslizumab 0 (0.0) 23 (2.9)
Long-term OCS 0 (0.0) 697 (44.1)
Baseline therapies
Nonmissing 28 (100.0) 1,580 (100.0)
Anti-IgE 9 (32.1) 212 (13.4) .004a,b
Anti-IL-4 0 (0) 2 (0.1) .576a
Long-term OCS 0 (0.0) 581 (36.7) —
Macrolide 1 (3.6) 78 (4.9) .596d
Add on to ICS and LABA
LAMA 11 (39.3) 503 (31.8) .402a
LTRA 14 (50.0) 443 (28.0) .011a,b
LAMA and LTRA 7 (25.0) 237 (15.0) .144a
Theophylline 2 (7.1) 188 (11.9) .765d
Data are presented as No. (%) or mean  SD. Statistically significant P values are shown in bold. BD ¼ bronchodilator; CRS ¼ chronic rhinosinusitis; — ¼
not compared; FENO ¼ fractional exhaled nitric oxide; ICS ¼ inhaled corticosteroid; ISAR ¼ International Severe Asthma Registry; LABA ¼ long-acting b2-







fTwo-sample test of proportions.(using the highest ever value) and impact of OCS into
account, both of which can confound phenotype
classification. We proposed a gradient approach (ie,
likelihood of eosinophilic asthma), rather than a
dichotomous approach, to severe asthma phenotypechestjournal.orgclassification in recognition of the inherent
heterogeneity within phenotypes and the fact that they
can occur in isolation or combination in any given
patient and may change over time, either because of the
natural history of the disease or as a consequence of823
% with eczema
Noneosinophilic (Grade 0) Eosinophilic (Grade 2 and 3)
% with FEV1/FVC < 0.7
% on Anti-IgE
% on LTRA add-on
% with BEC ≥ 300








% aged ≥ 55 y
% with onset > 18 y
Figure 3 – Spider plot showing the clinical and biomarker variable distribution pattern for the eosinophilic (n ¼ 1,580) and noneosinophilic (n ¼ 28)
severe asthma phenotype for the International Severe Asthma Registry prospective population. BEC ¼ blood eosinophil count; FENO ¼ fractional
exhaled nitric oxide; LTRA ¼ leukotriene receptor antagonist (add-on to inhaled corticosteroids plus long-acting b-agonist therapy); ppb ¼ parts per
billion.treatment.1 Finally, we pooled diverse data from large
severe asthma registries to provide a real-life phenotype
snapshot at the global and country levels, quantifying
and characterizing both the severe eosinophilic
phenotype and also the often-ignored noneosinophilic
severe asthma phenotype, which historically has been a
diagnosis of exclusion.
A gradient and multicomponent eosinophil
classification algorithm is useful to reflect heterogeneity
not only within severe asthma, but also within
eosinophilic and noneosinophilic phenotypes. Use of
elevated BEC as the sole marker for defining an
eosinophilic phenotype may be misleading for several
reasons. The amount of eosinophils in the blood is both
time-dependent and treatment-dependent; eosinophil
counts fluctuate in a circadian pattern and are also
reduced during OCS therapy.28,29 Additionally, a low
BEC does not necessarily rule out the presence of airway
eosinophilia. Its use as a single surrogate marker for
airway eosinophilia in patients with asthma “will lead to824 Original Researcha substantial number of false positives or false
negatives.”30 A combination of clinical parameters and
biomarkers may safeguard against phenotype
misclassification and is one explanation for the > 80% of
patients with severe eosinophilic asthma observed in the
present study. Both the Severe Asthma Research
Program and the Leicester cohorts have used this
combination approach.31
Using a multicomponent gradient eosinophil algorithm
to characterize eosinophilic and noneosinophilic
phenotypes of severe asthma within ISAR (Fig 1)
permitted us to take a phenotype snapshot.1 We found
that that the vast majority of patients (> 80%) in severe
asthma centers globally have background eosinophilic
asthma (regardless of the algorithm used) and that the
proportion of patients with a completely
noneosinophilic phenotype is very rare (only 1.6% in the
current study). Others recently validated our findings,
showing a similarly high prevalence of eosinophilic
asthma (83.4%), defined as $ 300 cells/mL ever in the[ 1 6 0 # 3 CHES T S E P T EM B E R 2 0 2 1 ]
past 10 years, in a real-life difficult-to-treat UK asthma
population.32 However, arguably the ISAR gradient
eosinophil algorithm affords a more practical means of
determining eosinophilic asthma status than reliance on
protracted, sequential BEC.
The low prevalence of noneosinophilic phenotype in the
present study could be the result of the strict
noneosinophilic phenotype definition used, OCS
overtreatment, possibly anti-IgE treatment and LTRA
treatment, which may have suppressed some algorithm
variables (eg, BEC), or a combination thereof.33,34 This
low-eosinophilic phenotype prevalence remained when
age at onset and FENO were removed as criteria from the
gradient algorithm. Those with an eosinophilic severe
asthma phenotype have an elevated BEC (ie,$ 150 cells/
mL), are more likely to have nasal polyps and FENO of $
25 parts per billion (by algorithm definition), are older,
and are more likely to have adult-onset asthma and
worse lung function (than those with noneosinophilic
severe asthma). Conversely, our preliminary findings,
based on small numbers, found that those with a
noneosinophilic severe asthma phenotype have a
relatively low BEC (ie, < 150 cells/mL), no nasal polyps,
low FENO (ie, < 25 parts per billion), and early-onset
disease and are more likely to be women, to have
eczema, and to be treated with anti-IgE and LTRA add-
on to inhaled corticosteroids plus long-acting b-agonist
therapy (presumably because of ineligibility for anti-IL-
5/5 receptor treatment by virtue of low BEC). This
finding highlights the lack of other treatment options
and the need to develop treatments targeted at this
often-overlooked subset of patients with severe asthma.
The higher likelihood of eczema reported relative to
patients with an eosinophilic phenotype may be the
result of the greater prevalence of OCS and biologic use
in the latter group, which may reduce the severity of
both conditions so they are not active.
In common with most severe asthma cohorts, we found
a clear predominance of women (regardless of
phenotype). Interestingly, the prevalence of male sex
seemed to be proportionately greater in the eosinophilic
group (37.1% vs 18.5%), which in conjunction with
older age and later disease onset seen in the eosinophilic
group aligns with the findings of Azim and colleagues,35
who recently identified a male, adult-onset, eosinophilic,
difficult asthma phenotype that so far has received scant
attention in the literature. Similarity of health care
resource use for both eosinophilic and noneosinophilicchestjournal.orgsevere asthma suggests comparable asthma severity
across phenotypes. Similarity across phenotypes for
asthma control and asthma attacks may be attributable
to the fact that ISAR selects patients who are more likely
to experience an asthma attack. However, this finding
may suggest that despite complete suppression of
eosinophilic inflammation (with corticosteroids or
biologic therapy) in those with definite eosinophilic
asthma, symptoms and asthma attacks can persist and
that other factors (besides the eosinophil) are important
(eg, comorbidities, health care access, and
socioeconomic factors). Characterization of
noneosinophilic mechanisms that persist when
eosinophilic inflammation has been suppressed warrants
further characterization. The relatively lower prevalence
of the severe eosinophilic phenotype in the US
retrospective population (74%) is attributed mainly to a
lack of nasal polyps and age at asthma onset data and
speaks to the benefit of the standardized, prospective
data collection and coding used in ISAR as well as the
importance of longitudinal assessment of BEC.
Table 3 compares this global view of eosinophilic
phenotype description with cluster analyses from three
large asthma cohorts (Severe Asthma Research
Program, Unbiased Biomarkers for Prediction of
Respiratory Disease, and Airways Disease Endotyping
for Personalized Therapeutics).15 All clusters identified
a predominance of eosinophilic clusters, but differed
in the size of the eosinophilic and noneosinophilic
clusters identified, ranging from 49% to 56% and
16% to 31%, respectively,36,37 and markedly differed
from the results of the current study (Table 3). These
differences in part may be the result of inclusion of
mild asthma in these clusters (eg, the percentage of
patients with an eosinophilic phenotype increases to
81.2% when patients with mild disease are discounted
from the Severe Asthma Research Program cohort)
because of differences in choice of variables and are
complicated by the inclusion of a mixed granulocyte
phenotype in the Unbiased Biomarkers for Prediction
of Respiratory Disease and the Airways Disease
Endotyping for Personalized Therapeutics cohorts,
which include neutrophilic types. Indeed, Burgel and
colleagues38 argue that cluster analyses should be
viewed as an exploratory analysis and that the results
should be validated using clinically relevant end points
in multiple cohorts of patients. Use of multiple clinical
biomarkers, a well-characterized cohort, and variables
that are treatable to define phenotypes (as in our825
TABLE 3 ] Comparison of ISAR Eosinophilic Phenotypes vs Clinical Cluster Analyses From Three Large, Well-Phenotyped Asthma Cohorts
ISAR Cohort (N ¼ 1,716) SARP Cluster (n ¼ 726)37 U-BIOPRED Cluster (n ¼ 82)36 ADEPT Clusters (n ¼ 156)36
Characteristics % Characteristics % Characteristics % Characteristics %
Early onset, mild, atopic,
eosinophilic (n ¼ 110)
Mild asthma, good lung function,
early onset, low inflammation
(n ¼ 25)
Mild, normal lung function, early
onset, low inflammation (n ¼ 28)
Eosinophilic (BEC $ 150
cells/mL), adult onset, high
FENO (> 25 ppb), nasal
polyps, older, worse lung
function
83.8 Early onset, moderate, atopic,
eosinophilic (n ¼ 321)
68.9 Moderate, hyperresponsive,
eosinophilic (n ¼ 32)
48.8 Moderate, atopic, mild reversible
obstruction, hyperresponsive,







granulocytic (n ¼ 8)
Severe uncontrolled, severe
reversible obstruction, mixed
granulocytic (n ¼ 35)
Early onset, severe atopic
reversible, obstruction,
eosinophilic (n ¼ 120)
Noneosinophilic (low BEC <
150 cells/mL), early onset,




1.6 late onset, long duration,
severe, fixed airflow
obstruction (n ¼ 116)
16.0 Mixed severity, mild reversible
obstruction, noneosinophilic,
neutrophilic (n ¼ 17)
20.7 Mixed severity, mild reversible
obstruction, noneosinophilic,
neutrophilic (n ¼ 49)
31.4
Table adapted from Carr et al15 (2018). ADEPT ¼ Airways Disease Endotyping for Personalized Therapeutics; BEC ¼ blood eosinophilic count; FENO ¼ fractional exhaled nitric oxide; ISAR ¼ International Severe Asthma
































study) may have a superior biological responsiveness
predictive value.3,39
One limitation of the study includes a potential selection
bias for the eosinophilic phenotype within ISAR.
Although the ISAR population may be enriched for
those with high BEC, frequent asthma attacks, and
suitability for biologic prescription in some countries
(eg, the United Kingdom), thus positively selecting for
the severe eosinophilic phenotype, this is not true for all
countries. Indeed, a recent study including data from 7
ISAR-participating countries (the United States, United
Kingdom, South Korea, Italy, Australia, New Zealand,
and Singapore) found that only 25.4% of patients with
severe asthma were receiving biologic therapy (either
anti-IgE or anti-IL-5).40 A similarly high prevalence of
eosinophilic asthma and low prevalence of
noneosinophilic asthma also has been reported in a
primary care cohort using the same eosinophil
phenotype gradient algorithm41 and in the actively
managed US EMR population presented in the current
study. Furthermore, a similarly low prevalence of
noneosinophilic asthma has been reported in the
Refractory Asthma Stratification Programme-UK
asthma cohort using a different algorithm.42 Our
algorithm is intended to aid phenotype classification and
does not capture all asthma subtypes, for instance, the
subtype of asthmatics with low BEC and elevated FENO
and nasal polyps who do respond well to anti-IL-4/13
therapy.43 This phenotype can be explored more fully
within ISAR when IL-4/13 use becomes more
widespread. Additional limitations include a reliance on
BEC rather than sputum eosinophil count, possibility of
recall bias (eg, for onset of asthma), and the large
imbalance in patient numbers between the groups whenchestjournal.orgdescribing demographic and clinical characteristics.
However, it should be noted that although sputum
induced by hypertonic saline generally is considered a
reliable, noninvasive method to assess and monitor
eosinophilia, it can be problematic in patients with
severe and uncontrolled asthma inducing airway
narrowing, failure to produce an adequate sputum
sample in about one-quarter of patients, or both.44
Blood eosinophilia is an accurate surrogate marker for
sputum eosinophils, with a reported ROC AUC of
89%.45
It is recommended that this gradient algorithm be
applied in a different severe asthma study population
with longitudinal BEC records to assess the specificity of
the eosinophil phenotype definition and to assess the
generalizability of the reported results. Future work
could evaluate the internal and external validity of the
gradient algorithm, could examine more fully the
eosinophil phenotype characteristics by country, could
characterize the ISAR cohort according to type 2 and
non-type 2 endotypes, and could examine overlap
between phenotypes and biomarkers.
Interpretation
This multicomponent, expert-endorsed, eosinophil
gradient algorithm, using variables readily accessible in
real life, has shown that the prevalence of the severe
asthma eosinophilic phenotype is higher than previously
thought and phenotypically distinct. Use of this
algorithm may enable physicians to ascertain what type
of asthma patients have, the components of the airway
disease, and its treatable traits, bringing us one step
closer to the practice of precision medicine and selection
of targeted phenotype-specific treatments.827
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